RNAi as new class of nanomedicines

Monika Dominska, Derek M. Dykxhoorn

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

RNA interference (RNAi)-based gene-silencing technologies provide a novel approach for the treatment of a variety of diseases through the sequence-specific silencing of gene expression. The application of small interfering RNA (siRNA) as potential therapeutic agents requires the development of clinically feasible delivery strategies that enhance their pharmacological properties. To be efective, siRNAs must be delivered to and taken up by specific target cells and tissues, enter the cytoplasm, and associate with the RNA-induced silencing complex (RISC) to guide the sequence-specific cleavage of appropriate messenger RNA (mRNA). This chapter will focus on recent progress made in the development of safe and efective therapeutic strategies for the siRNA-based silencing of gene expression.

Original languageEnglish (US)
Title of host publicationHandbook of Harnessing Biomaterials in Nanomedicine
PublisherPan Stanford Publishing Pte. Ltd.
Pages163-197
Number of pages35
ISBN (Print)9789814316460
DOIs
StatePublished - Jan 31 2012

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)
  • Engineering(all)

Cite this

Dominska, M., & Dykxhoorn, D. M. (2012). RNAi as new class of nanomedicines. In Handbook of Harnessing Biomaterials in Nanomedicine (pp. 163-197). Pan Stanford Publishing Pte. Ltd.. https://doi.org/10.4032/9789814364270